Alexion hikes forecast on big leap in Soliris sales; Zogenix hits back at Massachusetts restrictions on Zohydro;

@FiercePharma: Top-read special report: The top 10 pharma companies by 2013 revenue. Feature | Follow @FiercePharma

@TracyStaton: Novartis, GSK team up in consumer JV to save big money, gain big scale. More | Follow @TracyStaton

@EricPFierce: Gilead turns in eye-popping results because of huge sales of Sovaldi, $2.3B in Q1 sales for the hep C drug. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Allergan poison pill presages a battle against Valeant's $47B takeover. Story | Follow @CarlyHFierce

> Rare disease specialist Alexion Pharmaceuticals ($ALXN) hiked its full-year forecast again after its only marketed drug, Soliris, delivered a 67% increase in Q1 sales, to $567 million. Report

> After Massachusetts Gov. Deval Patrick backed away from banning its controversial new pain drug Zohydro, Zogenix ($ZGNX) balked at the restrictions Patrick chose to impose instead. Report

> GlaxoSmithKline ($GSK) set up a $500,000 endowment at the arts-oriented Barnes Foundation in Philadelphia, after selling off the art collection that once hung in its offices in that city. Report

> Merck ($MRK) tapped Catalent to make its new sublingual immunotherapies for allergies, Ragwitek and Grastek. Report

> AbbVie ($ABBV) is funding 10 scholarships for Canadian students suffering from Crohn's disease and ulcerative colitis. Report

Medical Device News

@FierceMedDev: Lombard Medical revives stateside IPO plans with a $55M debut. Article | Follow @FierceMedDev

@VarunSaxena2: BREAKING: Zimmer buying fellow orthopedics company Biomet for $13.35 billion. | Follow @VarunSaxena2

@EmilyWFierce: New genetic-bionic treatment for hearing loss could help improve pitch perception in those with cochlear implants. Article from Wired | Follow @EmilyWFierce

@MichaelGFierce: X-ray-activated nanoparticles release cancer-killing light deeper into tissue. More from FierceDrugDelivery | Follow @MichaelGFierce

> Varian's profits slip as revenue ticks up slightly. Story

> BioFire buy boosts bioMérieux earnings. Article

> Breast cancer screening company Quantason files for Chapter 11. More

Biotech News

@FierceBiotech: An international biotech tackles CRISPR gene editing tech with $25M bankroll. More | Follow @FierceBiotech

@JohnCFierce: You gotta give $AZN credit. They keep spinning. Beefing up PhIII, which should have been Soriot's initial focus. More from the FT | Follow @JohnCFierce

@DamianFierce: $CELG opens down 5%. Perhaps a $710M deal didn't thrill investors who just watched R&D costs drag profits. | Follow @DamianFierce

@EmilyMFierce: Genetically engineered mosquitoes could be vital weapon against malaria. More from The Guardian | Follow @EmilyMFierce

> Hyperion bets up to $570M on diabetes biotech Andromeda. More

> AstraZeneca continues to chop back, spotlights immuno-oncology PhIII. Report

> J&J snags FDA OK for rare blood disorder drug siltuximab. Article

Pharma Manufacturing News

> FDA is now reporting recalls still awaiting classification. News

> China's Sinovac gets $9.6M grant to build vaccine plant. Article

> Report: Industry's regulatory-centric focus for manufacturing will no longer cut it. More

> Bristol-Myers extends manufacturing pact with Samsung. Story

> Wockhardt smacked by state regulator in India. Report

> Regulatory issues crush India's drug export growth. Item

Vaccines News

> Sinovac scores $9.6M Chinese grant for new hand, foot and mouth disease vaccine. Article

> Tetanus shot stored at higher temperatures as effective as cold chain-stored jab. More

> Immune discovery puts vaccine for H. pylori closer in sight. Story

> MERS vaccine to ease outbreak within 6 months, virologist says. Item

> Novartis bids farewell to vaccines with $7.1B sale to GSK. News

> U.K. health secretary asks Novartis CEO for Bexsero price cut. Report

And Finally... More evidence for the welcome news that dark chocolate is a healthy snack. Report (sub. req.)